Search clinical trials for: apatinib

Total 2161 results

SWOG Cancer Research Network
National Cancer Institute (NCI)

Active, not recruiting

Testing the Addition of Ruxolitinib to the Usual Treatment (Tyrosine Kinase Inhibitors) for Chronic Myeloid Leukemia

Chronic Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive

United States
Shanghai Chest Hospital

Unknown

Apatinib in the Treatment of Recurrence or Metastasis of Esophageal Cancer

Recurrence | Metastasis | Esophageal Squamous Cell Carcinoma | Apatinib

China
Sun Yat-sen University

Unknown

Study on the Adverse Drug Reactions (ADRs) of Apatinib and Their Biomarker Correlations

Stage IV Cancer

China
Novartis Pharmaceuticals

Completed

A Phase I Study of Oral Asciminib (ABL001) in Patients With CML or Ph+ ALL

Chronic Myelogenous Leukemia | Philadelphia Chromosome-positive Acute Lymphoblastic Leukemia

Germany, Australia, Netherlands, Spain, Korea, Republic of, France, Japan, Italy, Singapore, United States
Jian Fang
Peking University First Hospital; Peking University Third Hospital; The Second...

Unknown

Apatinib in Advanced Non-squamous，NSCLC

Non-squamous Non-Small Cell Lung Cancer

China
Jiangsu HengRui Medicine Co., Ltd.
Fudan University

Completed

Dose Finding and Pharmacokinetics/Pharmacodynamics Study of Apatinib in the Treatment of Advanced Colorectal Cancer

Colorectal Cancer

China
Nanfang Hospital of Southern Medical University

Unknown

Observation of the Effect of Chemotherapy Combined With Tyrosinase Inhibitor on the Reactivation of CMV and EBV in Patients With Acute Lymphoblastic Leukemia

Leukemia, Lymphoblastic, Acute

China
Ruijin Hospital

Recruiting

A Umbrella Study in R/R PTCL Guided by Molecular Subtypes

Peripheral T Cell Lymphoma

China
National Cancer Institute (NCI)

Active, not recruiting

Imatinib Mesylate or Dasatinib in Treating Patients With Previously Untreated Chronic Phase Chronic Myelogenous Leukemia

Chronic Myeloid Leukemia, BCR-ABL1 Positive

United States, Canada
Boehringer Ingelheim

Completed

Afatinib in Subjects With Kidney Dysfunction

Renal Insufficiency

Germany
Sun Yat-sen University
Jiangsu HengRui Medicine Co., Ltd.

Recruiting

A Trial of Hepatic Arterial Infusion Combined With Apatinib and Camrelizumab Versus Apatinib and Camrelizumab for C-staged Hepatocellular Carcinoma in BCLC Classification (TRIPLET-III)

C-staged Hepatocellular Carcinoma in BCLC Classification

China
Fujian Medical University

Recruiting

A Study of TAE+HAIC Combined With Camrelizumab and Apatinib in the Treatment of Advanced Hepatocellular Carcinoma

Advanced Hepatocellular Carcinoma

China
Jiangsu HengRui Medicine Co., Ltd.

Completed

A Food Effect Study of Apatinib Mesylate in Healthy Subjects

Healthy Subjects

China
Sichuan Cancer Hospital and Research Institute

Unknown

Efficacy and Safety of Apatinib As Third Line Therapy in Patients With Advanced Ovarian Cancer

Angiogenesis Inhibitors，Ovarian Neoplasms

China
Sun Yat-sen University

Unknown

Apatinib in the Treatment of Advanced Non-squamous Non-small Cell Lung Cancer

Non-small Cell Lung Cancer

China
Ascentage Pharma Group Inc.
HealthQuest Pharma Inc.

Active, not recruiting

A Pivotal Study of HQP1351 in Patients With Chronic Myeloid Leukemia in Chronic Phase

Chronic Myeloid Leukemia, Chronic Phase

China
Medical College of Wisconsin
Memorial Sloan Kettering Cancer Center; Dana-Farber Cancer Institute; University... and other collaborators

Completed

The Life After Stopping Tyrosine Kinase Inhibitors Study (The LAST Study)

Leukemia, Myeloid, Chronic

United States
Wuhan Union Hospital, China

Not yet recruiting

Tucidinostat Plus Apatinib for Advanced Osteosarcoma

Osteosarcoma
Cancer Institute and Hospital, Chinese Academy...

Recruiting

Preoperative IMRT With Concurrent Apatinib for Localised Extremity or Trunk Sarcoma

Sarcoma,Soft Tissue | Trunk | Extremity | Intensity-modulated Radiotherapy | Major Wound Complications | Targetd Therapy

China
Yuhong Li

Completed

Apatinib for Esophageal Squamous Cell Cancer After the Failure of Standard Treatment (Poetry-1)

Esophageal Squamous Cell Carcinoma

China
Fan Yun, MD

Completed

Apatinib for Extensive Stage Small Cell Lung Cancer After Second/Third Line Chemotherapy.

Small Cell Lung Cancer

China
First Affiliated Hospital of Harbin Medical University

Terminated

Clinical Study of Apatinib in the Treatment of Platinum Resistant Recurrent Ovarian Cancer

Ovarian Cancer

China
The First Affiliated Hospital with Nanjing Medical...
Jiangsu HengRui Medicine Co., Ltd.; Beijing gene plus technology co., LTD

Completed

Apatinib in Refractory Colorectal Cancer

Colorectal Neoplasms

China
Shanghai Ninth People's Hospital Affiliated to...

Unknown

A Study of Apatinib in Recurrent/Metastatic Adenoid Cystic Carcinoma of the Head and Neck

Adenoid Cystic Carcinoma

China
Shanghai Ninth People's Hospital Affiliated to...

Unknown

Radiotherapy Concurrent With Apatinib in Advanced Soft Tissue and Bone Sarcomas of Head and Neck--RASS Study (RASS)

Sarcoma | Head and Neck Cancer | Soft Tissue and Bone Tumor

China
Jiangsu HengRui Medicine Co., Ltd.
Sun Yat-sen University

Completed

A Study of Apatinib in Patients With Advanced Non-squamous and Non-small Cell Lung Cancer

Non-Small-Cell Lung Cancer

China
Fudan University

Completed

Apatinib Versus Placebo as a Third Line Treatment in Patients With Advanced or Metastatic Gastric Cancer

Gastric Carcinoma

China
Beijing Sanbo Brain Hospital

Recruiting

Apatinib in the Treatment of Recurrent Atypical/Malignant Meningioma in Adults

Recurrent Atypical/Malignant Meningioma

China
Affiliated Hospital of Qinghai University

Completed

Apatinib for the Elderly Advanced Gastric Cancer

Gastric Cancer

China
The Affiliated Hospital of Qingdao University

Unknown

The Combination of Apatinib and Camerlizumab for Advanced Lung Cancer Patients With Muti-line Therapy

Lung Cancer

China
Jiangsu HengRui Medicine Co., Ltd.

Unknown

A Study to Evaluate the Pharmacokinetics of Apatinib in Subjects With Impaired Renal Function

Subjects With Impaired Renal Function and Healthy Subjects
Jiangsu HengRui Medicine Co., Ltd.
Fudan University; The 81 Hospital of PLA

Completed

Phase III Study of Apatinib Tablets in the Treatment of Advanced or Metastatic Gastric Cancer

Advanced or Metastatic Gastric Cancer

China
Jiangsu HengRui Medicine Co., Ltd.

Completed

A Trial of SHR-1210 (an Anti-PD-1 Inhibitor) in Combination With Apatinib and Fluzoparib in Patients With TNBC

Triple Negative Breast Cancer

China
West China Hospital
Jiangsu HengRui Medicine Co., Ltd.

Unknown

Apatinib Combine With Platinum-Based Doublet Chemotherapy for First-line Treatment of Advanced NSCLC

Lung Cancer | Non Small Cell Lung Cancer | Apatinib | Combination Chemotherapy

China
Fujian Cancer Hospital

Not yet recruiting

Fluzopari Combined With Apatinib for the Neoadjuvant Treatment of Unresectable Ovarian Cancer

Ovarian Cancer

China
Fudan University

Recruiting

Apatinib Monotherapy Versus Apatinib Combined With Camrelizumab for Third-line Treatment of Metastatic Gastric Cancer

Gastric Cancer | Metastasis

China
Di Wu

Recruiting

Neoadjuvant SHR-1210 Plus Apatinib for Resectable Stage III-IV Acral Melanoma

Acral Melanoma

China
Peking University People's Hospital

Completed

Apatinib for Inoperable Advanced Chondrosarcoma (AIAC)

Efficacy | Toxicity, Drug

China
Guangzhou Institute of Respiratory Disease
Jiangsu HengRui Medicine Co., Ltd.

Unknown

Efficacy and Safety of Apatinib as Third-line Therapy for Primary Pulmonary Lymphoepithelioid Carcinoma (Spark-AL003)

Lung Carcinoma

China
Cancer Institute and Hospital, Chinese Academy...

Unknown

Study of Apatinib as Third-line and Later Therapy in Patients With Small Cell Lung Cancer (SCLC)

Small Cell Lung Cancer

China
Tianjin Medical University Cancer Institute and...

Unknown

Phase 2 Trial of Apatinib Mesylate in Locally Advanced/Metastatic Differentiated Thyroid Carcinoma

Differentiated Thyroid Carcinoma

China
Tianjin Medical University Cancer Institute and...

Unknown

Study of Apatinib in Advanced Hepatocellular Carcinoma(HCC) (HCC)

Hepatocellular Carcinoma

China
Tianjin Medical University Cancer Institute and...

Unknown

A One-arm Exploratory Clinical Research Program Study of Apatinib in Advanced Metastatic Renal Cell Carcinoma Patients.

Metastatic Renal Cell Carcinoma
The First Affiliated Hospital of Zhengzhou University

Unknown

A Study of Apatinib for Advanced Hepatocellular Carcinoma Patients After First-line Treatment Failure

Hepatocellular Carcinoma
University of Jena
Novartis Pharmaceuticals; Ludwig-Maximilians - University of Munich

Active, not recruiting

Frontline Asciminib Combination in Chronic Phase CML (CMLXI)

Chronic Myeloid Leukemia

Germany
Novartis Pharmaceuticals

Active, not recruiting

A Study of Oral Asciminib Versus Other TKIs in Adult Patients With Newly Diagnosed Ph+ CML-CP

Chronic Myeloid Leukemia (CML) Philadelphia Chromosome Positive

United States, China, Hungary, Japan, Belgium, Germany, Canada, Singapore, Australia, Israel, Netherlands, Spain, Italy, Korea, Republic of, Bulgaria, France, United Kingdom, Czechia, Sweden, India, Malaysia, Denmark, Taiwan, Norway, Fi... and more
Peking University People's Hospital
Jiangsu HengRui Medicine Co., Ltd.

Recruiting

Apatinib With Ifosfamide Plus Etoposide for Relapsed or Refractory Osteosarcoma (OAIE) (OAIE)

Toxicity | Effect of Drug | Drug

China
Beijing Chest Hospital

Not yet recruiting

A Study of Camrelizumab Combined With Chemotherapy Sequential Camrelizumab Combined With Apatinib Treatment of Advanced NSCLC

Non-small Cell Lung Cancer
Henan Cancer Hospital

Recruiting

Camrelizumab Plus Apatinib as Maintenance Therapy in Extensive-stage Small-cell Lung Cancer (CAMERA)

Small Cell Lung Carcinoma

China
Sun Yat-sen University

Recruiting

Neoadjuvant Carilizumab and Apatinib for Recurrent High-Grade Glioma

Neoadjuvant Therapy | Apatinib | Carilizumab | Recurrent High-Grade Glioma

China

Search clinical trials for: apatinib

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Indonesia

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations